{"ticker": {"uuid": "9542732c-dd8b-415f-9b0f-63df1f29d967", "symbol": "AMLX", "name": "Amylyx Pharmaceuticals Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Drug Manufacturers - Specialty & Generic"}, "articles": [{"title": "Trade Alert: Chief Legal Officer & General Counsel Of Amylyx Pharmaceuticals Gina Mazzariello Has Sold Stock", "summary": "Gina Mazzariello, Chief Legal Officer & General Counsel of Amylyx Pharmaceuticals (NASDAQ:AMLX), recently sold US$539k worth of stock at US$17.96 per share, reducing her holding by 47%. This sale was the largest insider sale for the company in the last year, suggesting caution de", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amlx/amylyx-pharmaceuticals/news/trade-alert-chief-legal-officer-general-counsel-of-amylyx-ph", "source_name": "Simply Wall Street", "published_at": "2026-07-15T11:48:22", "published_display": "15 Jul 2026 11:48", "sentiment": "negative", "sentiment_pct": 35, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Sell: Gina Mazzariello Sells 30,000 Shares of Amylyx Pha", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPZjVtQTBnVmdRYVUtYmV6UlNXUzlhWnMyTk80NXlMdndJVXBxdXB2U0JqZ0dRWlo4NXllMXhXMmtsc3pxS3g3dFV6eVEtXzlfZzRmeHRTVmJpVVVXVWdCajNlLURZRllWanUyMGhOZ1IwS1haNEdoQTZHT09PQlBtUEtyNVJkUklaRWlfNDZ4RkdtdjFaREUzVkd6N1VIRjZZeG9sZXFIc2NjaXVVTGsxRmx1T2R0TEtCUkxsUng5UQ?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-13T22:33:33+00:00", "published_display": "13 Jul 2026 22:33", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amylyx Pharmaceuticals (AMLX) CLO sells 30,000 shares under 10b5-1 plan", "summary": "Amylyx Pharmaceuticals' Chief Legal Officer, Gina Mazzariello, sold a total of 30,000 common shares in two open-market transactions on July 9 and July 10, 2026. The sales were conducted under a Rule 10b5-1 trading plan adopted on April 9, 2026. Following these transactions, Mazza", "url": "https://www.stocktitan.net/sec-filings/AMLX/form-4-amylyx-pharmaceuticals-inc-insider-trading-activity-37c85572d8fd.html", "source_name": "Stock Titan", "published_at": "2026-07-13T19:40:43", "published_display": "13 Jul 2026 19:40", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amylyx Pharmaceuticals (AMLX) Proxy filing Summary", "summary": "Amylyx Pharmaceuticals (AMLX) has scheduled its Annual Meeting for June 4, 2026, to be held virtually, with proxy materials available online. Key agenda items include the election of two Class II directors, ratification of Deloitte & Touche LLP as the independent registered publi", "url": "https://quartr.com/events/amylyx-pharmaceuticals-inc-amlx-proxy-filing_oSGrAYCc", "source_name": "Quartr", "published_at": "2026-07-10T00:12:21", "published_display": "10 Jul 2026 00:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 Amylyx Pharmaceuticals For: 9 July By Investing.com", "summary": "This article from Investing.com reports on the filing of Form 144 by Amylyx Pharmaceuticals on July 9, 2026. Form 144 is typically used to notify the SEC of the intent to sell restricted securities. The brief article provides the date of the filing and mentions Amylyx Pharmaceuti", "url": "https://ng.investing.com/news/stock-market-news/form-144-amylyx-pharmaceuticals-for-9-july-93CH-2593926", "source_name": "Investing.com Nigeria", "published_at": "2026-07-09T21:50:00", "published_display": "09 Jul 2026 21:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] Amylyx Pharmaceuticals, Inc. SEC Filing", "summary": "This article details an SEC Form 144 filing by Amylyx Pharmaceuticals, Inc. (AMLX). The filing indicates a proposed sale of 30,000 common shares with an aggregate market value of $536,400. The shares were acquired on March 31, 2025, as Restricted Stock Units from the issuer, with", "url": "https://www.stocktitan.net/sec-filings/AMLX/144-amylyx-pharmaceuticals-inc-sec-filing-9502dbabe770.html", "source_name": "Stock Titan", "published_at": "2026-07-09T20:04:44", "published_display": "09 Jul 2026 20:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amylyx Pharmaceuticals (AMLX) M&A Announcement Summary", "summary": "Amylyx Pharmaceuticals (AMLX) has acquired avexitide for $35.1 million in cash, aiming to expand its pipeline into rare endocrine and metabolic diseases beyond neurodegenerative conditions. The acquisition aligns with the company's focus on high unmet medical needs like hyperinsu", "url": "https://quartr.com/events/amylyx-pharmaceuticals-inc-amlx-m-a-announcement_oSGrMtLO", "source_name": "Quartr", "published_at": "2026-07-09T01:39:17", "published_display": "09 Jul 2026 01:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amylyx Pharmaceuticals (AMLX) Q3 2024 earnings summary", "summary": "Amylyx Pharmaceuticals (AMLX) reported its Q3 2024 earnings, highlighting a strategic shift towards its advanced late-stage pipeline following the discontinuation of RELYVRIO/ALBRIOZA. The company is focusing on AMX0035 for Wolfram syndrome and PSP, and avexitide for PBH, which w", "url": "https://quartr.com/events/amylyx-pharmaceuticals-inc-amlx-q3-2024_oSGrMOk6", "source_name": "Quartr", "published_at": "2026-07-08T23:39:17", "published_display": "08 Jul 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Amylyx Pharmaceuticals (AMLX) A Bargain Following Russell Index Removals?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-07T07:58:12+00:00", "published_display": "07 Jul 2026 07:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Index Exit and Early ALS Data Could Be A Game Changer For Amylyx Pharmaceuticals (AMLX)", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-05T14:35:24+00:00", "published_display": "05 Jul 2026 14:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AMLX - Amylyx Pharmaceuticals Inc Dividends", "summary": "This article provides detailed financial data for Amylyx Pharmaceuticals Inc (AMLX), including its market performance, key financial ratios, and insider/institutional ownership. It highlights the company's stock price, market capitalization, income, sales, and various performance", "url": "https://finviz.com/stock?t=AMLX&ty=dv&=scroll", "source_name": "Finviz", "published_at": "2026-07-04T09:42:04", "published_display": "04 Jul 2026 09:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Companies Like Amylyx Pharmaceuticals (NASDAQ:AMLX) Are In A Position To Invest In Growth", "summary": "This article analyzes Amylyx Pharmaceuticals (NASDAQ:AMLX) and discusses its financial position to invest in growth. The company has a substantial cash reserve and minimal debt, providing flexibility for strategic investments. Key financial metrics such as cash runway, enterprise", "url": "https://www.moomoo.com/news/post/72403380/companies-like-amylyx-pharmaceuticals-nasdaq-amlx-are-in-a-position", "source_name": "Moomoo", "published_at": "2026-07-03T10:40:19", "published_display": "03 Jul 2026 10:40", "sentiment": "positive", "sentiment_pct": 69, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AMLX - Amylyx Pharmaceuticals Inc Latest SEC Filings", "summary": "This article provides detailed financial data and stock performance metrics for Amylyx Pharmaceuticals Inc (AMLX) as of July 2, 2026. It includes information on market capitalization, income, sales, P/E ratios, insider and institutional ownership, and year-to-date performance. Th", "url": "https://finviz.com/quote?t=AMLX&ta=1&p=d&ty=lf&b=1", "source_name": "Finviz", "published_at": "2026-07-02T21:10:10", "published_display": "02 Jul 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AMLX - Amylyx Pharmaceuticals Inc Earnings", "summary": "This article provides a detailed financial overview of Amylyx Pharmaceuticals Inc (AMLX). It includes key metrics such as market capitalization, sales, earnings per share, insider and institutional ownership, and various performance indicators. The data indicates recent positive ", "url": "https://finviz.com/stock?t=AMLX&ta=1&p=d&ty=ea&b=1", "source_name": "Finviz", "published_at": "2026-07-02T18:09:28", "published_display": "02 Jul 2026 18:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Amylyx Pharmaceuticals, Inc. (AMLX) Stock Ready for a Breakout Ahead of Key LUCIDITY Trial Data?", "summary": "Amylyx Pharmaceuticals (AMLX) is being eyed for a potential breakout, with Guggenheim raising its price target to $40 and upgrading it to a \"Best Idea\" ahead of Q3 LUCIDITY trial results for avexitide. The company also presented positive Phase 1 LUMINA trial data for AMX0114 in A", "url": "https://www.insidermonkey.com/blog/is-amylyx-pharmaceuticals-inc-amlx-stock-ready-for-a-breakout-ahead-of-key-lucidity-trial-data-1792042/?amp=1", "source_name": "Insider Monkey", "published_at": "2026-06-30T13:09:29", "published_display": "30 Jun 2026 13:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) on behalf of investors who purchased securities before November 11, 2022, and still hold them. The investigation seeks to determine if Amylyx and its officers ", "url": "https://natlawreview.com/press-releases/amylyx-pharmaceuticals-inc-amlx-investigation-bronstein-gewirtz-grossman-1", "source_name": "The National Law Review", "published_at": "2026-06-30T10:40:19", "published_display": "30 Jun 2026 10:40", "sentiment": "negative", "sentiment_pct": 18, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AMLX Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Amylyx Pharmaceuticals, Inc. (AMLX) stock, including analyst price targets, past performance, and future earning estimations. It states that analysts have a maximum price target of $40.00 and a minimum of $19.00, with the stock previously reac", "url": "https://www.tradingview.com/symbols/NASDAQ-AMLX/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-30T00:40:43", "published_display": "30 Jun 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amylyx Pharmaceuticals, Inc.(NasdaqGS:AMLX) dropped from Russell Microcap Value Benchmark Index", "summary": "Amylyx Pharmaceuticals, Inc. (NasdaqGS:AMLX) has been removed from the Russell Microcap Value Benchmark Index. This news follows previous announcements earlier the same day regarding its removal from other Russell indexes including the Small Cap Comp Value, Microcap, 3000 Value, ", "url": "https://www.marketscreener.com/news/amylyx-pharmaceuticals-inc-nasdaqgs-amlx-dropped-from-russell-microcap-value-benchmark-index-ce7f5fdfdb8af427", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T16:40:09", "published_display": "29 Jun 2026 16:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amylyx Pharmaceuticals, Inc.(NasdaqGS:AMLX) dropped from Russell Small Cap Comp Value Benchmark", "summary": "Amylyx Pharmaceuticals, Inc. (NasdaqGS:AMLX) has been removed from the Russell Small Cap Comp Value Benchmark, as reported by S&P Capital IQ. This news follows several other recent announcements that the company has been dropped from various Russell indices, including the Microca", "url": "https://www.marketscreener.com/news/amylyx-pharmaceuticals-inc-nasdaqgs-amlx-dropped-from-russell-small-cap-comp-value-benchmark-ce7f5fdede8afe2d", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T10:40:09", "published_display": "29 Jun 2026 10:40", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amylyx Pharmaceuticals, Inc.(NasdaqGS: AMLX) dropped from Russell Microcap Index", "summary": "Amylyx Pharmaceuticals, Inc. (NasdaqGS: AMLX) has been removed from the Russell Microcap Index, as announced on June 29, 2026. This news follows several other recent removals from various Russell indices, including the Russell 3000E Index and Russell Microcap Value Benchmark Inde", "url": "https://www.marketscreener.com/news/amylyx-pharmaceuticals-inc-nasdaqgs-amlx-dropped-from-russell-microcap-index-ce7f5fdedf80ff20", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T05:45:00", "published_display": "29 Jun 2026 05:45", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amylyx Pharmaceuticals, Inc.(NasdaqGS:AMLX) dropped from Russell 2500 Value Benchmark", "summary": "Amylyx Pharmaceuticals, Inc. (NasdaqGS:AMLX) has been removed from the Russell 2500 Value Benchmark. The company is a clinical-stage pharmaceutical firm focusing on four investigational therapies, including avexitide for Post-Bariatric Hypoglycemia and congenital HI, AMX0035 for ", "url": "https://www.marketscreener.com/news/amylyx-pharmaceuticals-inc-nasdaqgs-amlx-dropped-from-russell-2500-value-benchmark-ce7f5fded880f120", "source_name": "marketscreener.com", "published_at": "2026-06-28T21:11:00", "published_display": "28 Jun 2026 21:11", "sentiment": "negative", "sentiment_pct": 38, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "12 Best Low-Priced Pharma Stocks to Buy Right Now", "summary": "This article identifies Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) as one of the best low-priced pharma stocks to consider. Guggenheim recently raised its price target for AMLX to $40 and reaffirmed a Buy rating, elevating it to a \"Best Idea\" ahead of anticipated Phase 3 trial re", "url": "https://www.insidermonkey.com/blog/12-best-low-priced-pharma-stocks-to-buy-right-now-1790099/6/", "source_name": "Insider Monkey", "published_at": "2026-06-28T12:40:00", "published_display": "28 Jun 2026 12:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Amylyx Pharmaceuticals, Inc. \u2013 NASDAQ:AMLX", "summary": "This article displays the \"Price to sales forward\" metric for Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) on TradingView. It indicates that the market is closed, and no trades have occurred for this particular data point. The page provides a snapshot of financial data for the com", "url": "https://www.tradingview.com/symbols/NASDAQ-AMLX/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T21:40:56", "published_display": "27 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Amylyx Pharmaceuticals, Inc. \u2013 NASDAQ:AMLX", "summary": "The article focuses on the enterprise value to EBIT forward for Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX). It indicates that this financial metric is a key focus for investors tracking the company. The content appears to be a stub or a section from a financial data platform, hi", "url": "https://www.tradingview.com/symbols/NASDAQ-AMLX/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T21:09:30", "published_display": "27 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Amylyx Pharmaceuticals, Inc. \u2013 NASDAQ:AMLX", "summary": "This article provides the enterprise value to revenue forward for Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX). It indicates that the market was closed at the time of the information display and includes general financial data and market information related to the company on Tradi", "url": "https://www.tradingview.com/symbols/NASDAQ-AMLX/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T03:10:22", "published_display": "27 Jun 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Guggenheim Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Maintains Target Price $40", "summary": "Guggenheim has reiterated its Buy rating for Amylyx Pharmaceuticals (AMLX.US) and maintained its target price of $40. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance and future prospects.", "url": "https://www.moomoo.com/news/post/72108558/guggenheim-maintains-amylyx-pharmaceuticals-amlxus-with-buy-rating-maintains-target", "source_name": "Moomoo", "published_at": "2026-06-26T20:09:29", "published_display": "26 Jun 2026 20:09", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amylyx advancing ALS treatment in trial after early safety data is positive", "summary": "Amylyx's investigational ALS therapy, AMX0114, is progressing to higher doses in the LUMINA Phase 1 clinical trial after initial safety data showed it was well-tolerated at the lowest dose. While biomarkers of nerve damage remained stable at this dose, researchers believe higher ", "url": "https://alsnewstoday.com/news/als-treatment-amx0114-advances-lumina-trial-following-positive-safey-data/", "source_name": "ALS News Today", "published_at": "2026-06-26T19:10:22", "published_display": "26 Jun 2026 19:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Amylyx Pharmaceuticals, Inc. \u2013 NASDAQ:AMLX", "summary": "The article is a financial data page from TradingView focusing on the Enterprise Value to EBITDA forward for Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX). It indicates that the market was closed and no trades were made when the data was accessed, presenting the company's financial", "url": "https://www.tradingview.com/symbols/NASDAQ-AMLX/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T13:09:14", "published_display": "26 Jun 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Guggenheim Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Raises Target Price to $40", "summary": "Guggenheim has reiterated its Buy rating for Amylyx Pharmaceuticals (AMLX.US) and increased the target price to $40. This reflects a continued positive outlook from the analyst firm regarding the biopharmaceutical company's prospects.", "url": "https://www.moomoo.com/news/post/72040874/guggenheim-maintains-amylyx-pharmaceuticals-amlxus-with-buy-rating-raises-target", "source_name": "Moomoo", "published_at": "2026-06-26T07:09:30", "published_display": "26 Jun 2026 07:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amylyx Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:AMLX)", "summary": "This article provides financial actuals and estimates for Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX), covering its stock performance, analyst forecasts, and company financials. Key details include current stock price, historical highs and lows, market capitalization, and upcoming", "url": "https://www.tradingview.com/symbols/NASDAQ-AMLX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T07:09:15", "published_display": "26 Jun 2026 07:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amylyx Pharmaceuticals stock hits 52-week high at $18.65", "summary": "Amylyx Pharmaceuticals Inc. (AMLX) stock has reached a 52-week high of $18.65, though InvestingPro analysis suggests it is overvalued. The company has shown significant gains over the past year, with a 171.57% return, and continues to advance its drug candidates despite a recent ", "url": "https://www.investing.com/news/company-news/amylyx-pharmaceuticals-stock-hits-52week-high-at-1865-93CH-4761006", "source_name": "Investing.com", "published_at": "2026-06-25T15:40:22", "published_display": "25 Jun 2026 15:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Guggenheim raises Amylyx stock price target on PBH drug outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNU2pzRjJSQm5KcGFXb05OZlNhRHJuMTlMYTRwNWphQ0hidFBtMVIxaXltWDQwQ3dNMlFzUFNQZnBIcWNRU0szaGNib2JIUkk2TkRUNzNzeDFzYUtiMFFkWldqdVZwRmJyRnl4N1JISUJLWGIzY3BtVEJqcHE4YjQ0VVVoLXVyU2ZiaWJtYnpIcUlsWFRkUlFoQlFpNXNwdVZDak10YjM5WWpfSkU3Z051cXVqd1hqaWxNa1JSSkhPQ2U?oc=5", "source_name": "Investing.com", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amylyx Pharmaceuticals to Present Data from First-in-Human, Dose-Ranging Phase 1 LUMINA Trial of AMX0114 in ALS at ENCALS 2026", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/amylyx-pharmaceuticals-present-data-first-110000252.html", "source_name": "Business Wire", "published_at": "2026-06-23T11:00:00+00:00", "published_display": "23 Jun 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amylyx says ALS drug AMX0114 showed no serious safety issues", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPMmttaWV2bjk5VUlBNi1lOUxDUlpmbFNERlNVM1BJTzhRV0tzLVVfemRyVDBwNjVUQWtiZU14NGxvWGtlWDlwMWlaWm41Ny1RNWdXdXBSSC11S0h2c0xMelBvNDJKd1Rpa3Z2VHBzSGFYQXFURnhKRGZDeklCRjRfOW5rbTMtZE5XcVVfNlY4OHktX2daOVZHRWJ6enE4MVRZYVRxQUQwbDlDNExYUlFOcEdxdERHaC05dHc?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amylyx Pharmaceuticals Eyes Q3 Phase 3 Avexitide Readout as PBH Launch Plans Take Shape", "summary": "", "url": "https://finance.yahoo.com/m/f83511e3-bac6-38df-b375-a8ec419b9658/amylyx-pharmaceuticals-eyes.html", "source_name": "MarketBeat", "published_at": "2026-06-10T22:12:00+00:00", "published_display": "10 Jun 2026 22:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amylyx Pharmaceuticals Announces Poster Presentations at ENDO 2026", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/amylyx-pharmaceuticals-announces-poster-presentations-130000484.html", "source_name": "Business Wire", "published_at": "2026-06-08T13:00:00+00:00", "published_display": "08 Jun 2026 13:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Amylyx Pharmaceuticals (AMLX) Valuation After Its Recent Share Price Rebound", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxOcU5LRFhkZ2NMYjhrWGRWOGlwaWs0azZXMWZhbDdlVEFtX09sWEJyd1RwOUFaNHpTNTVmbmhJSGlsYkJhMi1uNUEteHNncFNwZmdmeFJzLWlKRUVNVE1BdFdicVZMSGRMZkVXUVpwZ1l2WkZSMlRuYzhtV0w0QjNjVktYRHQ2TEx5d1RCOXZBaEpSUWo4bm1EczI1YzRfanZCQnozMWJweVptZlE?oc=5", "source_name": "Market source", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director Karen Firestone adds Amylyx Pharmaceuticals (AMLX) shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNSkcxWHRXa3J0NHZpTzdocE43aUhEaW5MMnB4d0xWNGg3QW1Hb3dLVWl2d0Q1UWhLODVPUlhTUl9YZlgwcVVsV214Y2VfcUFUbTZPTDY3WWdjWHpValE4UUJ0WHhuVm9oQlNIRjJUVGtRazU2V1FxT0hscU5NVG1sMl9md1NCZFRUUnBsWDFrVk9sOXE5Z2FnTDJDV3pLdUZBOTJZRDdraGx0TngxR0Q1d3p2eFRMSmh4dHJLaQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amylyx Stock: Why the Full Pipeline Story Matters", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxPcWR4eFZNUXhxQ1AwZkMyY2RJYXdoaUZXeXBmNDNkRFZuTW5fRzkyT3liZU9kcjhQYTVYenBMczdIU0IzN0hxaDdadTFfcVYzRjJtbzlVTVE0czNCWVF0VmRwaUJHTVRfbmliOVY0RUJFX25fcDZsYVg4S2RPdXdfWGdtZ3hjS2JJTFdOM0Z3?oc=5", "source_name": "MarketBeat", "published_at": "2026-05-24T07:00:00+00:00", "published_display": "24 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amylyx Pharmaceuticals, Inc. (AMLX) Reports Q1 2026 Results and Pipeline Progress", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOTFZHa3VpRVF3X0xqR29RWjA0V1U2d1ZsX0RaUEJ5ZVNWN181c3Q2WmJERHlublI3U0ZiNE9yLUNkS3N4TXNiLVNnN3I1SDhyTU81bzNxN1NQTDNBOURXR19HaTYwYXcwcy1qNVJ5SlBUOExhUlhaM2ppVnpXWXhiMUhXc3Fpc09HaDFDalgwR2pWX0lEdkotTVBubHV6dVhEc0V1UUhCdHdWendx?oc=5", "source_name": "Market source", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Too Late To Consider Amylyx Pharmaceuticals (AMLX) After A 220% One Year Surge?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hikma Pharmaceuticals PLC stock (GB00B128J450): Dividend hike and $250M buyback", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxNX2ZfWkxLZDAyQUZNRU55RXhPVHI4dlZrTVVuc3RlV01XV0Jqd21vSDdYU0l3QkJOejBicXhjRXhQcmpkZHlVQ3BsRFE5ZFFxbFV3MWgtLUpndEZKTm1vbTAwaGlYMHEzWVVjNDVUYjFpM1hJS0NRTjdCc3pOeG9VNlg0QThScXpuV3lYNi0xY2NXMnkwdkFMYU8xYWU0WTIyaVdESzRVV2wxaThRazh6bTZCV1RPMWpJWW0tZy1qQUJVNjh6?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amylyx Readies Avexitide For PBH With Pivotal Trial And Valuation Gap", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-10T07:00:00+00:00", "published_display": "10 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amylyx Pharmaceuticals Reports First Quarter 2026 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxQbmgtVUxoOXpOaXdzcE1PNl82QUJZN0xLbzBmQk55a3N6bERyTjFoQnRReWRKSjBJSWkyakdtZG1ONGRNZnRGa1RFbkxlVlNPZUhKZHVFUGJJbDYzZ3Z0MF9NZmdPN2dIY3NFTXRWUmZCblNJQ0hKaGxLSlkxV0JCNUFYamE3Z1pWMUhKWGxERVhNLWEtZ2p6anVYSjM2VUlXLXRZMlhzSnlTTGZzVUt6VVd0emdSU2NjLUhmc2IteVp6UQ?oc=5", "source_name": "Business Wire", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amylyx Pharmaceuticals Q1 Earnings Call Highlights", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOb21LMVBZZmhKQ2tKQzIwYWduNVZWX01rY19vZFNLd1ozVGFqU0dNU01YVTZpTGxucFFtaUZSbkZNbDNwVEhpMURsOWRid3BQd19TU0wtX09ZRnR4NEJTaWh0cGVQZzYxeW5id0xMOXg0eHhETkZYNWtHSHpWUXNxWEJEWUVwaXdKZGVRQkRpTzkxdzFBbW5yUEViRktQV0U0NHp3SEpkVjRxQzA2?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amylyx Pharmaceuticals (AMLX) Winds Up Avexitide Phase 3 Lucidity Trial Enrollment", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPNk9MLVgwM0dzYTFTRWFSYU4teVdRQnBvR3ZnSFVJeDJ5QlF1MUFKNWllNE00aVd2dlhmWURsV2ZpMXBDb3A5MFVwNG9oOXAtOUkxa3RLc3dpMm9rUDAtcWRnajYwSmcwdjNwS3FLSXhRS0xvNElUaDh0Y2p2bjY2Z01GU2M5UGxXRUJ0eDVTdm4yMWZvTXZpZVZEYWY3TTY2a2t6aHlHc0NRS25DTXhvM3pR?oc=5", "source_name": "Market source", "published_at": "2026-03-31T07:00:00+00:00", "published_display": "31 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amylyx Pharmaceuticals: Back From The Dead (NASDAQ:AMLX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxPWDRkbDVZODZrZDhfMUktWmZ3SzB3SUxsbFhpQ18tTV9MOU45V0RNbGtPempMWlZpRERocWFoYTVZQ3FaLW5jZERvZ1JsN0VyS3M1T3h3T25qUlphOVk5ZnRPcmk1ZGp5WjFYRGlhcV9Bem1DaFo5ZjJDWkgwS2I5d1V1MFlPdkFrcGc?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-01-27T08:00:00+00:00", "published_display": "27 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amylyx pharma co-CEO Klee sells $1.88 million in AMLX stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNblMtWUJ6bGxDS01FVzJNS2E3QVNpenY2aUZfeGNCZFROZTY4cC1xLVdWZ0pYa3RONTZYM1lZU01BZTRTWkZFeHVKbjl2a3lCdEwtWlBHRVZKRXNVaDE5Qmt4TXA1Y2lSR2p2NjNsUjdhYWtIT0tDVC1zd1NmeVo3blFtdWw2dldGcWx2cDBNTWJtYXFvQzNFVzFrNjdQTk40Z0lVQVVOcnBPeFFXWnpWYUtXb3lMQ3hVUmlSTUdn?oc=5", "source_name": "Investing.com", "published_at": "2026-01-20T08:00:00+00:00", "published_display": "20 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amylyx Pharmaceuticals Stock (AMLX) Opinions on Insider Purchase and Clinical Data", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOc3RLUHNWOTlreGRpWGtlREsyNVhhMlluT0lUVkV3Y2s2aWlTaXh1SFJpOHA2QVlhdnpuQ2s4VTJldFRzSHBqYUNfYTdtRXlPNzVqOGNvNjQxLUtWZFFCQ044NUpfUThDdnhYbHBuUzJrejF2WVhiQk9JVEhDMUcxckdnTXFlLXlYbG1QTzcyNEhiaDR2clJTTmpnRk9DNGlsdXdLM2lvY2ZjU0I0N0xSQnBhQzMxbFRhTFFB?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-01-04T08:00:00+00:00", "published_display": "04 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're A Bit Worried About Amylyx Pharmaceuticals' (NASDAQ:AMLX) Cash Burn Situation", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-09-01T07:00:00+00:00", "published_display": "01 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amylyx Pharmaceuticals Discontinues Orion Program of Ax0035", "summary": "", "url": "https://news.google.com/rss/articles/CBMie0FVX3lxTE1BNlBHUEpTT0prSVVUU0pUMUJlcjhBSTVFSm9oUHNjeFh2YzVucnJycVBqamFEZnNNaVFPWE1DOWtQTW54cXF0QnhxeGFiOFlLaU1sY0tRUzdxaWpYTEU2aEtiU2RVT2VZX1M5S3hCTGdfWUt3Mk1YUXJXOA?oc=5", "source_name": "Pharmaceutical Executive", "published_at": "2025-08-28T07:00:00+00:00", "published_display": "28 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Trade Alert: Chief Legal Officer & General Counsel Of Amylyx Pharmaceuticals Gina Mazzariello Has Sold Stock", "summary": "Gina Mazzariello, Chief Legal Officer & General Counsel of Amylyx Pharmaceuticals (NASDAQ:AMLX), recently sold US$539k worth of stock at US$17.96 per share, reducing her holding by 47%. This sale was the largest insider sale for the company in the last year, suggesting caution de", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amlx/amylyx-pharmaceuticals/news/trade-alert-chief-legal-officer-general-counsel-of-amylyx-ph", "source_name": "Simply Wall Street", "published_at": "2026-07-15T11:48:22", "published_display": "15 Jul 2026 11:48", "sentiment": "negative", "sentiment_pct": 35, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Sell: Gina Mazzariello Sells 30,000 Shares of Amylyx Pha", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPZjVtQTBnVmdRYVUtYmV6UlNXUzlhWnMyTk80NXlMdndJVXBxdXB2U0JqZ0dRWlo4NXllMXhXMmtsc3pxS3g3dFV6eVEtXzlfZzRmeHRTVmJpVVVXVWdCajNlLURZRllWanUyMGhOZ1IwS1haNEdoQTZHT09PQlBtUEtyNVJkUklaRWlfNDZ4RkdtdjFaREUzVkd6N1VIRjZZeG9sZXFIc2NjaXVVTGsxRmx1T2R0TEtCUkxsUng5UQ?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-13T22:33:33+00:00", "published_display": "13 Jul 2026 22:33", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amylyx Pharmaceuticals (AMLX) CLO sells 30,000 shares under 10b5-1 plan", "summary": "Amylyx Pharmaceuticals' Chief Legal Officer, Gina Mazzariello, sold a total of 30,000 common shares in two open-market transactions on July 9 and July 10, 2026. The sales were conducted under a Rule 10b5-1 trading plan adopted on April 9, 2026. Following these transactions, Mazza", "url": "https://www.stocktitan.net/sec-filings/AMLX/form-4-amylyx-pharmaceuticals-inc-insider-trading-activity-37c85572d8fd.html", "source_name": "Stock Titan", "published_at": "2026-07-13T19:40:43", "published_display": "13 Jul 2026 19:40", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amylyx Pharmaceuticals (AMLX) Proxy filing Summary", "summary": "Amylyx Pharmaceuticals (AMLX) has scheduled its Annual Meeting for June 4, 2026, to be held virtually, with proxy materials available online. Key agenda items include the election of two Class II directors, ratification of Deloitte & Touche LLP as the independent registered publi", "url": "https://quartr.com/events/amylyx-pharmaceuticals-inc-amlx-proxy-filing_oSGrAYCc", "source_name": "Quartr", "published_at": "2026-07-10T00:12:21", "published_display": "10 Jul 2026 00:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 Amylyx Pharmaceuticals For: 9 July By Investing.com", "summary": "This article from Investing.com reports on the filing of Form 144 by Amylyx Pharmaceuticals on July 9, 2026. Form 144 is typically used to notify the SEC of the intent to sell restricted securities. The brief article provides the date of the filing and mentions Amylyx Pharmaceuti", "url": "https://ng.investing.com/news/stock-market-news/form-144-amylyx-pharmaceuticals-for-9-july-93CH-2593926", "source_name": "Investing.com Nigeria", "published_at": "2026-07-09T21:50:00", "published_display": "09 Jul 2026 21:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] Amylyx Pharmaceuticals, Inc. SEC Filing", "summary": "This article details an SEC Form 144 filing by Amylyx Pharmaceuticals, Inc. (AMLX). The filing indicates a proposed sale of 30,000 common shares with an aggregate market value of $536,400. The shares were acquired on March 31, 2025, as Restricted Stock Units from the issuer, with", "url": "https://www.stocktitan.net/sec-filings/AMLX/144-amylyx-pharmaceuticals-inc-sec-filing-9502dbabe770.html", "source_name": "Stock Titan", "published_at": "2026-07-09T20:04:44", "published_display": "09 Jul 2026 20:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amylyx Pharmaceuticals (AMLX) M&A Announcement Summary", "summary": "Amylyx Pharmaceuticals (AMLX) has acquired avexitide for $35.1 million in cash, aiming to expand its pipeline into rare endocrine and metabolic diseases beyond neurodegenerative conditions. The acquisition aligns with the company's focus on high unmet medical needs like hyperinsu", "url": "https://quartr.com/events/amylyx-pharmaceuticals-inc-amlx-m-a-announcement_oSGrMtLO", "source_name": "Quartr", "published_at": "2026-07-09T01:39:17", "published_display": "09 Jul 2026 01:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amylyx Pharmaceuticals (AMLX) Q3 2024 earnings summary", "summary": "Amylyx Pharmaceuticals (AMLX) reported its Q3 2024 earnings, highlighting a strategic shift towards its advanced late-stage pipeline following the discontinuation of RELYVRIO/ALBRIOZA. The company is focusing on AMX0035 for Wolfram syndrome and PSP, and avexitide for PBH, which w", "url": "https://quartr.com/events/amylyx-pharmaceuticals-inc-amlx-q3-2024_oSGrMOk6", "source_name": "Quartr", "published_at": "2026-07-08T23:39:17", "published_display": "08 Jul 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Amylyx Pharmaceuticals (AMLX) A Bargain Following Russell Index Removals?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-07T07:58:12+00:00", "published_display": "07 Jul 2026 07:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Index Exit and Early ALS Data Could Be A Game Changer For Amylyx Pharmaceuticals (AMLX)", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-05T14:35:24+00:00", "published_display": "05 Jul 2026 14:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AMLX - Amylyx Pharmaceuticals Inc Dividends", "summary": "This article provides detailed financial data for Amylyx Pharmaceuticals Inc (AMLX), including its market performance, key financial ratios, and insider/institutional ownership. It highlights the company's stock price, market capitalization, income, sales, and various performance", "url": "https://finviz.com/stock?t=AMLX&ty=dv&=scroll", "source_name": "Finviz", "published_at": "2026-07-04T09:42:04", "published_display": "04 Jul 2026 09:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Companies Like Amylyx Pharmaceuticals (NASDAQ:AMLX) Are In A Position To Invest In Growth", "summary": "This article analyzes Amylyx Pharmaceuticals (NASDAQ:AMLX) and discusses its financial position to invest in growth. The company has a substantial cash reserve and minimal debt, providing flexibility for strategic investments. Key financial metrics such as cash runway, enterprise", "url": "https://www.moomoo.com/news/post/72403380/companies-like-amylyx-pharmaceuticals-nasdaq-amlx-are-in-a-position", "source_name": "Moomoo", "published_at": "2026-07-03T10:40:19", "published_display": "03 Jul 2026 10:40", "sentiment": "positive", "sentiment_pct": 69, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AMLX - Amylyx Pharmaceuticals Inc Latest SEC Filings", "summary": "This article provides detailed financial data and stock performance metrics for Amylyx Pharmaceuticals Inc (AMLX) as of July 2, 2026. It includes information on market capitalization, income, sales, P/E ratios, insider and institutional ownership, and year-to-date performance. Th", "url": "https://finviz.com/quote?t=AMLX&ta=1&p=d&ty=lf&b=1", "source_name": "Finviz", "published_at": "2026-07-02T21:10:10", "published_display": "02 Jul 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AMLX - Amylyx Pharmaceuticals Inc Earnings", "summary": "This article provides a detailed financial overview of Amylyx Pharmaceuticals Inc (AMLX). It includes key metrics such as market capitalization, sales, earnings per share, insider and institutional ownership, and various performance indicators. The data indicates recent positive ", "url": "https://finviz.com/stock?t=AMLX&ta=1&p=d&ty=ea&b=1", "source_name": "Finviz", "published_at": "2026-07-02T18:09:28", "published_display": "02 Jul 2026 18:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Amylyx Pharmaceuticals, Inc. (AMLX) Stock Ready for a Breakout Ahead of Key LUCIDITY Trial Data?", "summary": "Amylyx Pharmaceuticals (AMLX) is being eyed for a potential breakout, with Guggenheim raising its price target to $40 and upgrading it to a \"Best Idea\" ahead of Q3 LUCIDITY trial results for avexitide. The company also presented positive Phase 1 LUMINA trial data for AMX0114 in A", "url": "https://www.insidermonkey.com/blog/is-amylyx-pharmaceuticals-inc-amlx-stock-ready-for-a-breakout-ahead-of-key-lucidity-trial-data-1792042/?amp=1", "source_name": "Insider Monkey", "published_at": "2026-06-30T13:09:29", "published_display": "30 Jun 2026 13:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) on behalf of investors who purchased securities before November 11, 2022, and still hold them. The investigation seeks to determine if Amylyx and its officers ", "url": "https://natlawreview.com/press-releases/amylyx-pharmaceuticals-inc-amlx-investigation-bronstein-gewirtz-grossman-1", "source_name": "The National Law Review", "published_at": "2026-06-30T10:40:19", "published_display": "30 Jun 2026 10:40", "sentiment": "negative", "sentiment_pct": 18, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AMLX Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Amylyx Pharmaceuticals, Inc. (AMLX) stock, including analyst price targets, past performance, and future earning estimations. It states that analysts have a maximum price target of $40.00 and a minimum of $19.00, with the stock previously reac", "url": "https://www.tradingview.com/symbols/NASDAQ-AMLX/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-30T00:40:43", "published_display": "30 Jun 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amylyx Pharmaceuticals, Inc.(NasdaqGS:AMLX) dropped from Russell Microcap Value Benchmark Index", "summary": "Amylyx Pharmaceuticals, Inc. (NasdaqGS:AMLX) has been removed from the Russell Microcap Value Benchmark Index. This news follows previous announcements earlier the same day regarding its removal from other Russell indexes including the Small Cap Comp Value, Microcap, 3000 Value, ", "url": "https://www.marketscreener.com/news/amylyx-pharmaceuticals-inc-nasdaqgs-amlx-dropped-from-russell-microcap-value-benchmark-index-ce7f5fdfdb8af427", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T16:40:09", "published_display": "29 Jun 2026 16:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amylyx Pharmaceuticals, Inc.(NasdaqGS:AMLX) dropped from Russell Small Cap Comp Value Benchmark", "summary": "Amylyx Pharmaceuticals, Inc. (NasdaqGS:AMLX) has been removed from the Russell Small Cap Comp Value Benchmark, as reported by S&P Capital IQ. This news follows several other recent announcements that the company has been dropped from various Russell indices, including the Microca", "url": "https://www.marketscreener.com/news/amylyx-pharmaceuticals-inc-nasdaqgs-amlx-dropped-from-russell-small-cap-comp-value-benchmark-ce7f5fdede8afe2d", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T10:40:09", "published_display": "29 Jun 2026 10:40", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amylyx Pharmaceuticals, Inc.(NasdaqGS: AMLX) dropped from Russell Microcap Index", "summary": "Amylyx Pharmaceuticals, Inc. (NasdaqGS: AMLX) has been removed from the Russell Microcap Index, as announced on June 29, 2026. This news follows several other recent removals from various Russell indices, including the Russell 3000E Index and Russell Microcap Value Benchmark Inde", "url": "https://www.marketscreener.com/news/amylyx-pharmaceuticals-inc-nasdaqgs-amlx-dropped-from-russell-microcap-index-ce7f5fdedf80ff20", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T05:45:00", "published_display": "29 Jun 2026 05:45", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amylyx Pharmaceuticals, Inc.(NasdaqGS:AMLX) dropped from Russell 2500 Value Benchmark", "summary": "Amylyx Pharmaceuticals, Inc. (NasdaqGS:AMLX) has been removed from the Russell 2500 Value Benchmark. The company is a clinical-stage pharmaceutical firm focusing on four investigational therapies, including avexitide for Post-Bariatric Hypoglycemia and congenital HI, AMX0035 for ", "url": "https://www.marketscreener.com/news/amylyx-pharmaceuticals-inc-nasdaqgs-amlx-dropped-from-russell-2500-value-benchmark-ce7f5fded880f120", "source_name": "marketscreener.com", "published_at": "2026-06-28T21:11:00", "published_display": "28 Jun 2026 21:11", "sentiment": "negative", "sentiment_pct": 38, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "12 Best Low-Priced Pharma Stocks to Buy Right Now", "summary": "This article identifies Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) as one of the best low-priced pharma stocks to consider. Guggenheim recently raised its price target for AMLX to $40 and reaffirmed a Buy rating, elevating it to a \"Best Idea\" ahead of anticipated Phase 3 trial re", "url": "https://www.insidermonkey.com/blog/12-best-low-priced-pharma-stocks-to-buy-right-now-1790099/6/", "source_name": "Insider Monkey", "published_at": "2026-06-28T12:40:00", "published_display": "28 Jun 2026 12:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Amylyx Pharmaceuticals, Inc. \u2013 NASDAQ:AMLX", "summary": "This article displays the \"Price to sales forward\" metric for Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) on TradingView. It indicates that the market is closed, and no trades have occurred for this particular data point. The page provides a snapshot of financial data for the com", "url": "https://www.tradingview.com/symbols/NASDAQ-AMLX/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T21:40:56", "published_display": "27 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Amylyx Pharmaceuticals, Inc. \u2013 NASDAQ:AMLX", "summary": "The article focuses on the enterprise value to EBIT forward for Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX). It indicates that this financial metric is a key focus for investors tracking the company. The content appears to be a stub or a section from a financial data platform, hi", "url": "https://www.tradingview.com/symbols/NASDAQ-AMLX/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T21:09:30", "published_display": "27 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Amylyx Pharmaceuticals, Inc. \u2013 NASDAQ:AMLX", "summary": "This article provides the enterprise value to revenue forward for Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX). It indicates that the market was closed at the time of the information display and includes general financial data and market information related to the company on Tradi", "url": "https://www.tradingview.com/symbols/NASDAQ-AMLX/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T03:10:22", "published_display": "27 Jun 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Guggenheim Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Maintains Target Price $40", "summary": "Guggenheim has reiterated its Buy rating for Amylyx Pharmaceuticals (AMLX.US) and maintained its target price of $40. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance and future prospects.", "url": "https://www.moomoo.com/news/post/72108558/guggenheim-maintains-amylyx-pharmaceuticals-amlxus-with-buy-rating-maintains-target", "source_name": "Moomoo", "published_at": "2026-06-26T20:09:29", "published_display": "26 Jun 2026 20:09", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amylyx advancing ALS treatment in trial after early safety data is positive", "summary": "Amylyx's investigational ALS therapy, AMX0114, is progressing to higher doses in the LUMINA Phase 1 clinical trial after initial safety data showed it was well-tolerated at the lowest dose. While biomarkers of nerve damage remained stable at this dose, researchers believe higher ", "url": "https://alsnewstoday.com/news/als-treatment-amx0114-advances-lumina-trial-following-positive-safey-data/", "source_name": "ALS News Today", "published_at": "2026-06-26T19:10:22", "published_display": "26 Jun 2026 19:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Amylyx Pharmaceuticals, Inc. \u2013 NASDAQ:AMLX", "summary": "The article is a financial data page from TradingView focusing on the Enterprise Value to EBITDA forward for Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX). It indicates that the market was closed and no trades were made when the data was accessed, presenting the company's financial", "url": "https://www.tradingview.com/symbols/NASDAQ-AMLX/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T13:09:14", "published_display": "26 Jun 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Guggenheim Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Raises Target Price to $40", "summary": "Guggenheim has reiterated its Buy rating for Amylyx Pharmaceuticals (AMLX.US) and increased the target price to $40. This reflects a continued positive outlook from the analyst firm regarding the biopharmaceutical company's prospects.", "url": "https://www.moomoo.com/news/post/72040874/guggenheim-maintains-amylyx-pharmaceuticals-amlxus-with-buy-rating-raises-target", "source_name": "Moomoo", "published_at": "2026-06-26T07:09:30", "published_display": "26 Jun 2026 07:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amylyx Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:AMLX)", "summary": "This article provides financial actuals and estimates for Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX), covering its stock performance, analyst forecasts, and company financials. Key details include current stock price, historical highs and lows, market capitalization, and upcoming", "url": "https://www.tradingview.com/symbols/NASDAQ-AMLX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T07:09:15", "published_display": "26 Jun 2026 07:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amylyx Pharmaceuticals stock hits 52-week high at $18.65", "summary": "Amylyx Pharmaceuticals Inc. (AMLX) stock has reached a 52-week high of $18.65, though InvestingPro analysis suggests it is overvalued. The company has shown significant gains over the past year, with a 171.57% return, and continues to advance its drug candidates despite a recent ", "url": "https://www.investing.com/news/company-news/amylyx-pharmaceuticals-stock-hits-52week-high-at-1865-93CH-4761006", "source_name": "Investing.com", "published_at": "2026-06-25T15:40:22", "published_display": "25 Jun 2026 15:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Guggenheim raises Amylyx stock price target on PBH drug outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNU2pzRjJSQm5KcGFXb05OZlNhRHJuMTlMYTRwNWphQ0hidFBtMVIxaXltWDQwQ3dNMlFzUFNQZnBIcWNRU0szaGNib2JIUkk2TkRUNzNzeDFzYUtiMFFkWldqdVZwRmJyRnl4N1JISUJLWGIzY3BtVEJqcHE4YjQ0VVVoLXVyU2ZiaWJtYnpIcUlsWFRkUlFoQlFpNXNwdVZDak10YjM5WWpfSkU3Z051cXVqd1hqaWxNa1JSSkhPQ2U?oc=5", "source_name": "Investing.com", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amylyx Pharmaceuticals to Present Data from First-in-Human, Dose-Ranging Phase 1 LUMINA Trial of AMX0114 in ALS at ENCALS 2026", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/amylyx-pharmaceuticals-present-data-first-110000252.html", "source_name": "Business Wire", "published_at": "2026-06-23T11:00:00+00:00", "published_display": "23 Jun 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amylyx says ALS drug AMX0114 showed no serious safety issues", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPMmttaWV2bjk5VUlBNi1lOUxDUlpmbFNERlNVM1BJTzhRV0tzLVVfemRyVDBwNjVUQWtiZU14NGxvWGtlWDlwMWlaWm41Ny1RNWdXdXBSSC11S0h2c0xMelBvNDJKd1Rpa3Z2VHBzSGFYQXFURnhKRGZDeklCRjRfOW5rbTMtZE5XcVVfNlY4OHktX2daOVZHRWJ6enE4MVRZYVRxQUQwbDlDNExYUlFOcEdxdERHaC05dHc?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amylyx Pharmaceuticals Eyes Q3 Phase 3 Avexitide Readout as PBH Launch Plans Take Shape", "summary": "", "url": "https://finance.yahoo.com/m/f83511e3-bac6-38df-b375-a8ec419b9658/amylyx-pharmaceuticals-eyes.html", "source_name": "MarketBeat", "published_at": "2026-06-10T22:12:00+00:00", "published_display": "10 Jun 2026 22:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amylyx Pharmaceuticals Announces Poster Presentations at ENDO 2026", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/amylyx-pharmaceuticals-announces-poster-presentations-130000484.html", "source_name": "Business Wire", "published_at": "2026-06-08T13:00:00+00:00", "published_display": "08 Jun 2026 13:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Amylyx Pharmaceuticals (AMLX) Valuation After Its Recent Share Price Rebound", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxOcU5LRFhkZ2NMYjhrWGRWOGlwaWs0azZXMWZhbDdlVEFtX09sWEJyd1RwOUFaNHpTNTVmbmhJSGlsYkJhMi1uNUEteHNncFNwZmdmeFJzLWlKRUVNVE1BdFdicVZMSGRMZkVXUVpwZ1l2WkZSMlRuYzhtV0w0QjNjVktYRHQ2TEx5d1RCOXZBaEpSUWo4bm1EczI1YzRfanZCQnozMWJweVptZlE?oc=5", "source_name": "Market source", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director Karen Firestone adds Amylyx Pharmaceuticals (AMLX) shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNSkcxWHRXa3J0NHZpTzdocE43aUhEaW5MMnB4d0xWNGg3QW1Hb3dLVWl2d0Q1UWhLODVPUlhTUl9YZlgwcVVsV214Y2VfcUFUbTZPTDY3WWdjWHpValE4UUJ0WHhuVm9oQlNIRjJUVGtRazU2V1FxT0hscU5NVG1sMl9md1NCZFRUUnBsWDFrVk9sOXE5Z2FnTDJDV3pLdUZBOTJZRDdraGx0TngxR0Q1d3p2eFRMSmh4dHJLaQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amylyx Stock: Why the Full Pipeline Story Matters", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxPcWR4eFZNUXhxQ1AwZkMyY2RJYXdoaUZXeXBmNDNkRFZuTW5fRzkyT3liZU9kcjhQYTVYenBMczdIU0IzN0hxaDdadTFfcVYzRjJtbzlVTVE0czNCWVF0VmRwaUJHTVRfbmliOVY0RUJFX25fcDZsYVg4S2RPdXdfWGdtZ3hjS2JJTFdOM0Z3?oc=5", "source_name": "MarketBeat", "published_at": "2026-05-24T07:00:00+00:00", "published_display": "24 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amylyx Pharmaceuticals, Inc. (AMLX) Reports Q1 2026 Results and Pipeline Progress", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOTFZHa3VpRVF3X0xqR29RWjA0V1U2d1ZsX0RaUEJ5ZVNWN181c3Q2WmJERHlublI3U0ZiNE9yLUNkS3N4TXNiLVNnN3I1SDhyTU81bzNxN1NQTDNBOURXR19HaTYwYXcwcy1qNVJ5SlBUOExhUlhaM2ppVnpXWXhiMUhXc3Fpc09HaDFDalgwR2pWX0lEdkotTVBubHV6dVhEc0V1UUhCdHdWendx?oc=5", "source_name": "Market source", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Too Late To Consider Amylyx Pharmaceuticals (AMLX) After A 220% One Year Surge?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hikma Pharmaceuticals PLC stock (GB00B128J450): Dividend hike and $250M buyback", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxNX2ZfWkxLZDAyQUZNRU55RXhPVHI4dlZrTVVuc3RlV01XV0Jqd21vSDdYU0l3QkJOejBicXhjRXhQcmpkZHlVQ3BsRFE5ZFFxbFV3MWgtLUpndEZKTm1vbTAwaGlYMHEzWVVjNDVUYjFpM1hJS0NRTjdCc3pOeG9VNlg0QThScXpuV3lYNi0xY2NXMnkwdkFMYU8xYWU0WTIyaVdESzRVV2wxaThRazh6bTZCV1RPMWpJWW0tZy1qQUJVNjh6?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amylyx Readies Avexitide For PBH With Pivotal Trial And Valuation Gap", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-10T07:00:00+00:00", "published_display": "10 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amylyx Pharmaceuticals Reports First Quarter 2026 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxQbmgtVUxoOXpOaXdzcE1PNl82QUJZN0xLbzBmQk55a3N6bERyTjFoQnRReWRKSjBJSWkyakdtZG1ONGRNZnRGa1RFbkxlVlNPZUhKZHVFUGJJbDYzZ3Z0MF9NZmdPN2dIY3NFTXRWUmZCblNJQ0hKaGxLSlkxV0JCNUFYamE3Z1pWMUhKWGxERVhNLWEtZ2p6anVYSjM2VUlXLXRZMlhzSnlTTGZzVUt6VVd0emdSU2NjLUhmc2IteVp6UQ?oc=5", "source_name": "Business Wire", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amylyx Pharmaceuticals Q1 Earnings Call Highlights", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOb21LMVBZZmhKQ2tKQzIwYWduNVZWX01rY19vZFNLd1ozVGFqU0dNU01YVTZpTGxucFFtaUZSbkZNbDNwVEhpMURsOWRid3BQd19TU0wtX09ZRnR4NEJTaWh0cGVQZzYxeW5id0xMOXg0eHhETkZYNWtHSHpWUXNxWEJEWUVwaXdKZGVRQkRpTzkxdzFBbW5yUEViRktQV0U0NHp3SEpkVjRxQzA2?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amylyx Pharmaceuticals (AMLX) Winds Up Avexitide Phase 3 Lucidity Trial Enrollment", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPNk9MLVgwM0dzYTFTRWFSYU4teVdRQnBvR3ZnSFVJeDJ5QlF1MUFKNWllNE00aVd2dlhmWURsV2ZpMXBDb3A5MFVwNG9oOXAtOUkxa3RLc3dpMm9rUDAtcWRnajYwSmcwdjNwS3FLSXhRS0xvNElUaDh0Y2p2bjY2Z01GU2M5UGxXRUJ0eDVTdm4yMWZvTXZpZVZEYWY3TTY2a2t6aHlHc0NRS25DTXhvM3pR?oc=5", "source_name": "Market source", "published_at": "2026-03-31T07:00:00+00:00", "published_display": "31 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amylyx Pharmaceuticals: Back From The Dead (NASDAQ:AMLX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxPWDRkbDVZODZrZDhfMUktWmZ3SzB3SUxsbFhpQ18tTV9MOU45V0RNbGtPempMWlZpRERocWFoYTVZQ3FaLW5jZERvZ1JsN0VyS3M1T3h3T25qUlphOVk5ZnRPcmk1ZGp5WjFYRGlhcV9Bem1DaFo5ZjJDWkgwS2I5d1V1MFlPdkFrcGc?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-01-27T08:00:00+00:00", "published_display": "27 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amylyx pharma co-CEO Klee sells $1.88 million in AMLX stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNblMtWUJ6bGxDS01FVzJNS2E3QVNpenY2aUZfeGNCZFROZTY4cC1xLVdWZ0pYa3RONTZYM1lZU01BZTRTWkZFeHVKbjl2a3lCdEwtWlBHRVZKRXNVaDE5Qmt4TXA1Y2lSR2p2NjNsUjdhYWtIT0tDVC1zd1NmeVo3blFtdWw2dldGcWx2cDBNTWJtYXFvQzNFVzFrNjdQTk40Z0lVQVVOcnBPeFFXWnpWYUtXb3lMQ3hVUmlSTUdn?oc=5", "source_name": "Investing.com", "published_at": "2026-01-20T08:00:00+00:00", "published_display": "20 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amylyx Pharmaceuticals Stock (AMLX) Opinions on Insider Purchase and Clinical Data", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOc3RLUHNWOTlreGRpWGtlREsyNVhhMlluT0lUVkV3Y2s2aWlTaXh1SFJpOHA2QVlhdnpuQ2s4VTJldFRzSHBqYUNfYTdtRXlPNzVqOGNvNjQxLUtWZFFCQ044NUpfUThDdnhYbHBuUzJrejF2WVhiQk9JVEhDMUcxckdnTXFlLXlYbG1QTzcyNEhiaDR2clJTTmpnRk9DNGlsdXdLM2lvY2ZjU0I0N0xSQnBhQzMxbFRhTFFB?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-01-04T08:00:00+00:00", "published_display": "04 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're A Bit Worried About Amylyx Pharmaceuticals' (NASDAQ:AMLX) Cash Burn Situation", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7AFBVV95cUxNaU9GMmoyZjF3MWpDOC00U2pxN0lwZlJtVmx6cnlncV9aQk5YYVNHWVhfN01obW9KQkQzOUdZZmw4LWdwQ2F0RHkwUVdvd2RZTkdDaUNORGE3bnRCT3pkQkJuY3laNTJoN2ZQM25JOU5EckJaRHdtRnlmbktQR2p5eEhNdllGMG1iWlppcVlrdGNCWEZQTTBxa3h2WWRTaDNJTERsMkxROTl3elpKclJUSXpMN0Fyektxc2RCUm1sZ1N4a0ZndzNMNDE1dnExV2pCMTRlSm8zcG50OGItakh2amFOR29iQk45ODlYUNIB8gFBVV95cUxQb2dGNVJGSDl4UG9tcFJGN2pUX2VqUm5Vdndja3FjcWRXN0VPOHI2MkhzNHhsSVBNTUZxTURZaGFCT1k2M2l2UUdYcHpIUXJ6b01YMXpYYWxZeFV3S3BNRW1SV0wwUmZ0aFdiVnI3bXVVenN2aDFPaDdld0lWU0g3QS1ncWVfV1gxUzhhOWhFcmJIUXYwX1RYcmNkMUxreGMxVnZpektVM01SUkwxbF95OUZvZ2J2Tk44bndRZk56emQzY3dUeUFUTXJRTXJDcXFNRXhUcWpYaXpHVWtTVFJyMGNmU2lyOHJ1QW8tT2trd0VzUQ?oc=5", "source_name": "simplywall.st", "published_at": "2025-09-01T07:00:00+00:00", "published_display": "01 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amylyx Pharmaceuticals Discontinues Orion Program of Ax0035", "summary": "", "url": "https://news.google.com/rss/articles/CBMie0FVX3lxTE1BNlBHUEpTT0prSVVUU0pUMUJlcjhBSTVFSm9oUHNjeFh2YzVucnJycVBqamFEZnNNaVFPWE1DOWtQTW54cXF0QnhxeGFiOFlLaU1sY0tRUzdxaWpYTEU2aEtiU2RVT2VZX1M5S3hCTGdfWUt3Mk1YUXJXOA?oc=5", "source_name": "Pharmaceutical Executive", "published_at": "2025-08-28T07:00:00+00:00", "published_display": "28 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 81, "total_relevant": 51, "sentiment_summary": {"positive": 11, "negative": 7, "neutral": 33, "score": 52, "total": 51, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 81, "events": [{"event": "general", "label": "Market update", "weight": 17.4, "count": 31}, {"event": "earnings", "label": "Earnings", "weight": 3.85, "count": 7}, {"event": "analyst", "label": "Analyst action", "weight": 2.75, "count": 5}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.65, "count": 3}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}], "positive_events": 11, "negative_events": 7}, "market_context": {"has_market_context": true, "latest_close": 17.77, "latest_week": "2026-07-10", "one_week_move": -2.7, "four_week_move": 21.8, "twelve_week_move": -3.2, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.486635, "market_dynamics_buy_signal": false, "relative_strength": 13.6701, "fair_value_gap": 81.5, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "positive", "expectation_probability": 55.3874, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-2.7% over one week, +21.8% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 61, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 6}, {"label": "simplywall.st", "count": 5}, {"label": "Stock Titan", "count": 4}, {"label": "Market source", "count": 4}, {"label": "Quartr", "count": 3}, {"label": "Finviz", "count": 3}, {"label": "Moomoo", "count": 3}, {"label": "www.marketscreener.com", "count": 3}], "tiers": [{"label": "Direct company coverage", "count": 51}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 31}, {"label": "Earnings", "count": 7}, {"label": "Analyst action", "count": 5}, {"label": "Regulatory and legal", "count": 3}, {"label": "Balance sheet", "count": 2}, {"label": "Deals and strategy", "count": 1}, {"label": "Guidance", "count": 1}, {"label": "Capital return", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "52/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "81/100 classification confidence."}, {"label": "Company focus", "value": "51", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-2.7% over one week, +21.8% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Negative", "tone": "negative", "text": "Trade Alert: Chief Legal Officer & General Counsel Of Amylyx Pharmaceuticals Gina Mazzariello Has Sold Stock"}], "updated_at": "2026-07-16T11:44:05.056342+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}